Petlife Pharmaceuticals, Inc.
PTLF · OTC
8/31/2017 | 8/31/2016 | 8/31/2015 | 8/31/2014 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $221 | $60 |
| Gross Profit | $0 | $0 | -$221 | -$60 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $73 |
| G&A Expenses | $22,385 | $3,687 | $0 | $0 |
| SG&A Expenses | $22,385 | $3,687 | $1,711 | $1,379 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $270 | $0 | $0 | $0 |
| Operating Expenses | $22,655 | $3,687 | $1,711 | $1,452 |
| Operating Income | -$22,655 | -$3,687 | -$1,932 | -$1,512 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$601 | $0 | $0 | $0 |
| Pre-Tax Income | -$23,257 | -$3,687 | -$1,932 | -$1,512 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$23,257 | -$3,687 | -$1,932 | -$1,512 |
| % Margin | – | – | – | – |
| EPS | -0.33 | -0.4 | -0.17 | -0.2 |
| % Growth | 17.5% | -135.3% | 15% | – |
| EPS Diluted | -0.33 | -0.4 | -0.17 | -0.2 |
| Weighted Avg Shares Out | 68,805 | 9,124 | 11,460 | 8,023 |
| Weighted Avg Shares Out Dil | 68,805 | 9,124 | 11,460 | 8,023 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $384 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$22,873 | -$3,687 | -$1,932 | -$1,512 |
| % Margin | – | – | – | – |